A Chinese study has identified small-molecule compounds that can selectively reduce levels of the mutant Huntingtin (HTT) protein involved in the pathogenesis of Huntington's disease (HD), and possibly other neurodegenerative diseases involving mutant protein accumulation.
A Chinese study has identified small-molecule compounds that can selectively reduce levels of the mutant Huntingtin (HTT) protein involved in the pathogenesis of Huntington's disease (HD), and possibly other neurodegenerative diseases involving mutant protein accumulation.
BOSTON, Mass. – KRAS used to be the poster child for undruggability. No more. Amgen Inc. and Mirati Therapeutics Inc. are in the clinic with KRAS inhibitors. Boehringer Ingelheim GmbH is planning to join them by the end of the year. And multiple other companies are moving programs forward.
Chinese researchers have developed the first green tea-triggered genetic control system for future gene- and cell-based precision medicine applications, and then used it to treat diabetes in mice and monkeys, they reported in the Oct. 23, 2019, issue of Science Translational Medicine.
Two very different roles were reported for the protein REST last week. In adults, REST activation appeared to extend lifespan by reducing overall brain activity. Principal investigator Bruce Yankner, professor of genetics at Harvard Medical School and co-director of the Paul F. Glenn Center for the Biology of Aging, told BioWorld MedTech that in postmortem brain samples of individuals who had had no cognitive impairments at the time of their death, his team found "a correlation between down-regulation of excitation and extended longevity."
RSS
